a structural basis is provided for the loss of Keap1 function and gain of Nrf2 function in lung cancer cells

peroxiredoxin 1, but not NF-E2-related factor 2, has a role in non-small cell lung cancer recurrence and progression

Keap1 prevents activation of Nrf2 and lung cancer cell growth

Targeting Nrf2 activity in lung cancers, particularly those with Keap1 mutations, could be a promising strategy to inhibit tumor growth and circumvent chemoresistance.

NFE2L2 mutations might play a role in tumor prognosis of squamous cell carcinoma of the lung.

RNAi-mediated lowering of Nrf2 in non-small-cell lung cancer cells led to increase in ROS; radiation-induced formation of protein carbonyls were higher in Nrf2-depleted lung cancer cells, suggesting increased lethality of radiation in absence of Nrf2

The Nuclear expression of Nrf2 in malignant lung cancer cells may play a role in resistance to platinum-based treatment in squamous cell carcinoma.

Nuclear factor erythroid-derived 2-like 2 and its stabilizing protein DJ1 affect the prognosis of patients with lung cancer by inducing an elevated stress response to oxidative damage.

The variants in the Nrf2 gene are associated with an increased risk for lung cancer.

Report nuclear factor E2-related factor 2 dependent overexpression of sulfiredoxin and peroxiredoxin III in human lung cancer.

We found a statistically significant correlation between the presence of kelch-like ECH-associated protein 1/Nrf2 mutations and increased multidrug-resistant protein-3 messenger RNA levels in non-small cell lung carcinoma patient samples.

An increased NRF2 gene copy number may correlate with clinicopathological features in lung cancer patients.

Knockdown of NRF2 in multiple lung tumor cell lines sensitized the cells to the effects of several chemotherapeutic agents.

Increased MRP3 gene expression correlates with NRF2 mutations in lung squamous cell carcinomas.

NRF2 gene mutations played a role in the prognosis of patients with squamous cell carcinoma of the lung.

study found weakened transcription of the Nrf2 gene provides a basis for the development of lung cancers, possibly through the reduced expression of cytoprotective enzymes

High NRF2 expression is associateed with lung carcinogenesis.

Data indicate that SNP homozygous (c.-617A/A) alleles in the transcription factor NRF2 NRF2 gene are associated with female non-smokers with lung adenocarcinoma and regarded as a prognostic biomarker.

action of thymidine phosphorylase in non-small cell lung cancer: crosstalk with Nrf2 and HO-1

Our findings illuminate the mechanistic details of KRAS-mediated drug resistance and provide a preclinical rationale to improve the management of lung tumors harboring KRAS mutations with NRF2 pathway inhibitors

Our data suggest that Nrf2-mediated ABCG2 over expression in lung adenocarcinoma SP (side population) cells might responsible for chemotherapy failure.

Data suggest that KEAP1 (kelch-like ECH-associated protein 1) mutations (such as those observed in lung cancer patients) affect conformation/folding/stability of KEAP1 and its binding affinity for ligands NRF2 and PTMA (prothymosin alpha).

Our study points to the relevance of LAPTM4B expression to NSCLC pathogenesis as well as to the probable role of LAPTM4B/NRF2 signaling in promoting lung cancer cell survival.

Finally, the effect of NGAL down-regulation on the growth of human lung adenocarcinoma was determined in BALB/c nude mice.

mutations in NRF2 gene is associated with non-small cell lung cancer.

Mutant p53 may confer cisplatin resistance via upregulation of Nrf2 expression in non-small cell lung carcinoma.

NFE2L2-mediated gene expression reflects lung cancer severity and progression. [meta-analysis]

Studies indicate a negative impact of nuclear factor erythroid 2-like factor 2 (Nrf2) signal on non-small cell lung cancer (NSCLC) patients' survival.

The modification of NRF2 or KEAP1 expression in non-small cell lung cancer cell lines disrupted downstream gene expression and cell sensitivity to platinum-based drugs.

It provides novel insights into Nrf2-mediated of cell proliferation in non-small cell lung cancer (NSCLC) and may facilitate therapeutic development against NSCLC.

ESI induces protective autophagy of lung cancer cells through Nrf2-p62-keap1 feedback loop

miR-155 mediated arsenic trioxide resistance by upregulating the Nrf2 signaling pathway, but downregulating cellular apoptosis in lung cancer cells.

study revealed that Nrf2 contributes to pancreatic carcinogenesis in a way distinct from the chemoresistance of lung and esophagus

Data indicate that kelch-Like ECH-associated protein 1 (KEAP1)/nuclear factor (erythroid-derived 2)-like 2 protein (NRF2)-mutant lung cancer is a microenvironmentally distinct, biologically heterogeneous, and clinically underestimated disease.

Study found that miR1443p could regulate the cisplatin resistance of lung cancer cells via Nrf2.

Nrf2 expression was not correlated with prognosis in non-small cell lung cancer

CDO1 is preferentially silenced by promoter methylation in human non-small cell lung cancers (NSCLC) harboring mutations in KEAP1, the negative regulator of NRF2. CDO1 silencing promotes proliferation of NSCLC by limiting the futile metabolism of cysteine to the wasteful and toxic byproducts cysteine sulfinic acid and sulfite (SO3(2-)), and depletion of cellular NADPH.

This is the first study that has described the effects of KEAP1 silencing on the regulation of NRF2 activity in lung carcinoids cells. The epigenetic deregulation of the KEAP1/NRF2 by a KEAP1 promoter hypermethylation system appears to be a frequent event in lung carcinoids.

The activated Nrf2 inhibits the Fbxo22-dependent degradation of Bach1 via induction of Ho1 expression. lung cancer cells with high levels of Nrf2 display also high levels of Bach1, the latter promoting metastasis through activation of pro-metastatic genes transcription.

We have demonstrated that FAM129B in cancer promotes Nrf2 activity by reducing its ubiquitination through competition with Nrf2 for Keap1 binding via its DLG and ETGE motifs. In addition, FAM129B reduces chemosensitivity by augmenting Nrf2 antioxidative signaling and confers poor prognosis in breast and lung cancer

mutations in the KEAP1/NFE2L2 pathway occur in approximately 7% of lung adenocarcinomas with activating EGFR mutations at diagnosis. Patients with KEAP1/NFE2L2/CUL3 mutations display relative intrinsic resistance to EGFR TKIs with reduced time to treatment failure.

mutations in the NEF2L2 gene are over represented in subset of lung adenocarcinoma that exhibit rapid progression and chemotherapy resistance features.

Acetaminophen sensitizing erastin-induced ferroptosis via modulation of Nrf2/heme oxygenase-1 signaling pathway in non-small-cell lung cancer.

Role of KEAP1/NFE2L2 mutations in the Chemotherapeutic Response of Patients with Non-Small Cell lung cancer.

Evidence has shown that the NRF2 pathway is frequently altered in lung cancer. NRF2 activation influences many of the hallmarks of cancer and their signaling pathways, as apoptosis, proliferation, angiogenesis, metastasis, and metabolic reprogramming. Constitutive activation of NRF2 promotes cancer development as well as resistance to chemotherapy and radiotherapy leading to a poor prognosis in lung cancer patients. [revi

Deregulation of UCA1 expression may be involved in the development of chemoresistance to cisplatin in the treatment of non-small-cell lung cancer via regulating the signaling pathway of microRNA-495/NRF2.

Study describes comprehensive metabolic profiling of non-small-cell lung cancer (NSCLC) cell lines according to the NRF2 activation status, and suggests the presence of alternative mechanisms that induce the activation of the NRF2 pathway in NSCLC cell lines.

Flumethasone enhances the efficacy of chemotherapeutic drugs in lung cancer by inhibiting Nrf2 signaling pathway.

Nrf2/ARE pathway activation is involved in negatively regulating heat-induced apoptosis in non-small cell lung cancer cells.

Cytoplasmic, but not nuclear Nrf2 expression, is associated with inferior survival and relapse rate and response to platinum-based chemotherapy in non-small cell lung cancer.

Prognostic and clinicopathological significance of NRF2 expression in non-small cell lung cancer: A meta-analysis.

Nrf2 deficient mice are sensitive to chemical carcinogens and exhibit a high-level of KRAS mutation independent lung cancer initiation.

NRF2 mutation is associated with lung Carcinogenesis.

results confirmed a protective role for Nrf2 in late-stage carcinogenesis and, unexpectedly, suggest that activation of Nrf2 in immune cells may be advantageous for preventing or treating lung cancer